Treatment of fibrous dysplasia: focus on denosumab
- 29 December 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 22 (3) , 397-405
Abstract
Fibrous dysplasia (FD) is a rare bone disease that is associated with various endocrine conditions, such as McCune Albright syndrome. It manifests as abnormal osteolysis, multiple fractures, or def...Keywords
Funding Information
- funded
This publication has 49 references indexed in Scilit:
- Denosumab treatment for fibrous dysplasiaJournal of Bone and Mineral Research, 2012
- Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer PatientsPLOS ONE, 2011
- Gs G protein–coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formationJournal of Bone and Mineral Research, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKLJournal of Bone and Mineral Research, 2009
- Osteoclasts: What Do They Do and How Do They Do It?The American Journal of Pathology, 2007
- Medical Therapy in Adults With Fibrous Dysplasia of BoneJournal of Bone and Mineral Research, 2006
- The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelingCytokine & Growth Factor Reviews, 2004
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2004
- Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome.Journal of Clinical Investigation, 1996